Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, it's definitely undervalued and due to run soon imo
$TWSI Receives Regulatory Approval from China's FDA
By: staff reporter, John Bodger
Last Updated: June 5, 2015 12:13 PM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc., received regulatory approval from the China Food and Drug Administration (CFDA) to market and sell products into China. HemCon has commercially entered the market this month by accepting an order through a distributor on the mainland.
HemCon's launch into the Chinese market will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion, and TWSI FDA approval in China now sets stage for sharp revenue growth in 2015.
TWSI also holds US FDA approval for their host of wound care products as well.
Phase 2 Funding from NIH
In addition, TWSI recently was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.30 per share.
About TriStar Wellness Solution, Inc.
TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com
$TWSI Receives Regulatory Approval from China's FDA
By: staff reporter, John Bodger
Last Updated: June 5, 2015 12:13 PM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc., received regulatory approval from the China Food and Drug Administration (CFDA) to market and sell products into China. HemCon has commercially entered the market this month by accepting an order through a distributor on the mainland.
HemCon's launch into the Chinese market will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion, and TWSI FDA approval in China now sets stage for sharp revenue growth in 2015.
TWSI also holds US FDA approval for their host of wound care products as well.
Phase 2 Funding from NIH
In addition, TWSI recently was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.30 per share.
About TriStar Wellness Solution, Inc.
TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com
$TWSI looking great. $.40 in no time, imo!
TWSI gets phase 2 funding...breakout!!!
TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
China FDA Approval
In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.
TWSI gets phase 2 funding...breakout!!!
TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
China FDA Approval
In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.
$TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
By: staff reporter, John Bodger
Last Updated: May 21, 2015 8:43 AM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
China FDA Approval
In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.
About TriStar Wellness Solution, Inc.
TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com
$TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
By: staff reporter, John Bodger
Last Updated: May 21, 2015 8:43 AM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).
Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.
Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.
China FDA Approval
In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.
TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.
About TriStar Wellness Solution, Inc.
TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com
Great find! GM to all. Let's go $TWSI!!
Get ready, guys. This is running to .40 imo!
TWSI breaking out! I'm not leaving till at least $1.00
Not bad at all, they're steadily moving back, closer to their rightful place. Should AT LEAST be a .4 company!
$TWSI -> NIH funding for prostate cancer product (level 2 thin)
* gets funding from NIH for prostate cancer blood control product
* also just got China FDA approval, sales have begun
* has US FDA approval as well
Level 2 super thin...asking .17, then .245 is up
http://www.otcmarkets.com/stock/twsi/quote
this could run to $1.00...breakout coming!!!
$TWSI -> NIH funding for prostate cancer product (level 2 thin)
* gets funding from NIH for prostate cancer blood control product
* also just got China FDA approval, sales have begun
* has US FDA approval as well
Level 2 super thin...asking .17, then .245 is up
http://www.otcmarkets.com/stock/twsi/quote
this could run to $1.00...breakout coming!!!
$TWSI -> NIH funding for prostate cancer product (level 2 thin)
* gets funding from NIH for prostate cancer blood control product
* also just got China FDA approval, sales have begun
* has US FDA approval as well
Level 2 super thin...asking .17, then .245 is up
http://www.otcmarkets.com/stock/twsi/quote
this could run to $1.00...breakout coming!!!
$TWSI (.10) about to report strong earnings
- 24 million shares OS
- low float, fast runner
- China entry, US military sales
- Revenues growing, projecting profitability
asking .10....then .175, .25
http://www.otcmarkets.com/stock/twsi/quote
Grab some before solid earnings come out
$TWSI (.10) about to report strong earnings
- 24 million shares OS
- low float, fast runner
- China entry, US military sales
- Revenues growing, projecting profitability
asking .10....then .175, .25
http://www.otcmarkets.com/stock/twsi/quote
Grab some before solid earnings come out
$TWSI (.10) about to report strong earnings
- 24 million shares OS
- low float, fast runner
- China entry, US military sales
- Revenues growing, projecting profitability
asking .10....then .175, .25
http://www.otcmarkets.com/stock/twsi/quote
Grab some before solid earnings come out
$TWSI only 26000 shares left @ .13, then .18, ,25
Real operating company, growing revenues, low float and shares OS....look how few shares are left till .25+
http://www.otcmarkets.com/stock/twsi/quote
$TWSI only 26000 shares left @ .13, then .18, ,25
Real operating company, growing revenues, low float and shares OS....look how few shares are left till .25+
http://www.otcmarkets.com/stock/twsi/quote
$TWSI only 26000 shares left @ .13, then .18, ,25
Real operating company, growing revenues, low float and shares OS....look how few shares are left till .25+
http://www.otcmarkets.com/stock/twsi/quote
$TWSI level 2 super thin (.18, then .25), chart breakout coming!!!
Look how thin level 2 is for TWSI....shows 5000 @ .18, then .25 up
http://www.otcmarkets.com/stock/twsi/quote
- Sales to China
- US military sales
- Revenues growing
- Possible buyout target
- $5 million in revs for 2014
- $15 to $20 million for 2015
- To become profitable in 2015
Once .18 goes .25 is a major breakout of 200 day moving average.....get ready for the run
5000 @ .18...then .25
level 2 looks super thin from .18 to .35
http://www.otcmarkets.com/stock/twsi/quote
trying to free up some cash from other trades to grab anything down here
$TWSI HemCon Medical Technologies Launches into Chinese Market
PORTLAND, Ore., April 7, 2015 /PRNewswire/ -- TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, through its subsidiary, HemCon Medical Technologies, Inc has received regulatory approval from the China Food and Drug Administration (CFDA) to market and sell products into China. HemCon has commercially entered the market this month by accepting an order through a distributor on the mainland. HemCon's launch into the Chinese market will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion.
Photo - http://photos.prnewswire.com/prnh/20150406/196695
Photo - http://photos.prnewswire.com/prnh/20150406/196696
HemCon has prior experience in the pan-Asian market having successfully established a wound care product line in Japan with their partner ZERIA Pharmaceutical.
Michael Wax, President and CEO said, "With our initial Chinese order in hand, combined with the Chinese government's approval for import of our dressings, we are looking ahead to building a robust business in a rapidly growing market. We have expectations to participate in the fast growing pan-Asian health care industry and specifically the increasing demand for wound care in China."
About HemCon Medical Technologies
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. The Company has subsidiaries in Ireland and the Czech Republic. For more information, please visit www.hemcon.com.
About TriStar Wellness Solutions
TriStar Wellness Solutions®, Inc. (OTCQB:TWSI) is a health and wellness company that targets opportunities in the advanced wound care marketplace. TriStar is the owner of HemCon Medical Technologies Inc., a company dedicated to saving lives through innovative wound care solutions.
Forward-Looking Statement
This press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.
Contact:
Stephanie Wiegman
Tel: (503) 245-0459
$TWSI HemCon Medical Technologies Launches into Chinese Market
PORTLAND, Ore., April 7, 2015 /PRNewswire/ -- TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, through its subsidiary, HemCon Medical Technologies, Inc has received regulatory approval from the China Food and Drug Administration (CFDA) to market and sell products into China. HemCon has commercially entered the market this month by accepting an order through a distributor on the mainland. HemCon's launch into the Chinese market will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion.
Photo - http://photos.prnewswire.com/prnh/20150406/196695
Photo - http://photos.prnewswire.com/prnh/20150406/196696
HemCon has prior experience in the pan-Asian market having successfully established a wound care product line in Japan with their partner ZERIA Pharmaceutical.
Michael Wax, President and CEO said, "With our initial Chinese order in hand, combined with the Chinese government's approval for import of our dressings, we are looking ahead to building a robust business in a rapidly growing market. We have expectations to participate in the fast growing pan-Asian health care industry and specifically the increasing demand for wound care in China."
About HemCon Medical Technologies
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. The Company has subsidiaries in Ireland and the Czech Republic. For more information, please visit www.hemcon.com.
About TriStar Wellness Solutions
TriStar Wellness Solutions®, Inc. (OTCQB:TWSI) is a health and wellness company that targets opportunities in the advanced wound care marketplace. TriStar is the owner of HemCon Medical Technologies Inc., a company dedicated to saving lives through innovative wound care solutions.
Forward-Looking Statement
This press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.
Contact:
Stephanie Wiegman
Tel: (503) 245-0459
It's quiet here, but TWSI is holding up well
$TWSI Begins Medical Wound Care Product Sales into China
By: staff reporter, John Bodger
Last Updated: April 21, 2015 12:58 PM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTCQB: TWSI) a leading developer and marketer of advanced wound care products, recently announced that through their subsidiary, HemCon Medical Technologies, Inc they had received regulatory approval from the China Food and Drug Administration (CFDA) to sell their medical products into China.
TWSI announced it had commercially entered the Chinese market this month by accepting an order through a distributor on the mainland. HemCon's launch into the Chinese market includes their full portfolio of wound care solutions, which are protected by patents both in China and throughout the world, and now positions them in the wound care market in China which is estimated at $1.2 billion.
HemCon has prior experience in the pan-Asian market having successfully established a wound care product line in Japan with their partner ZERIA Pharmaceutical.
Michael Wax, President and CEO commented in a recent press release, "With our initial Chinese order in hand, combined with the Chinese government's approval for import of our dressings, we are looking ahead to building a robust business in a rapidly growing market. We have expectations to participate in the fast growing pan-Asian health care industry and specifically the increasing demand for wound care in China."
TWSI currently traded on the OTCQB exchange, and has only around 24 million shares issued and outstanding. Based on their growing US and military sales, low shares outstanding, and now entry into the Chinese medical product market, TWSI stock has real potential to make a run back to $1.00 a share again.
TWSI current stock quote
http://www.otcmarkets.com/stock/twsi/quote
About HemCon Medical Technologies, Inc.
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com
Full article and website:
www.wallstreetnewscast.com/news/2015/04/twsi-china-1842.html
$TWSI Begins Medical Wound Care Product Sales into China
By: staff reporter, John Bodger
Last Updated: April 21, 2015 12:58 PM EST
(NEW YORK)--TriStar Wellness Solutions, Inc. (OTCQB: TWSI) a leading developer and marketer of advanced wound care products, recently announced that through their subsidiary, HemCon Medical Technologies, Inc they had received regulatory approval from the China Food and Drug Administration (CFDA) to sell their medical products into China.
TWSI announced it had commercially entered the Chinese market this month by accepting an order through a distributor on the mainland. HemCon's launch into the Chinese market includes their full portfolio of wound care solutions, which are protected by patents both in China and throughout the world, and now positions them in the wound care market in China which is estimated at $1.2 billion.
HemCon has prior experience in the pan-Asian market having successfully established a wound care product line in Japan with their partner ZERIA Pharmaceutical.
Michael Wax, President and CEO commented in a recent press release, "With our initial Chinese order in hand, combined with the Chinese government's approval for import of our dressings, we are looking ahead to building a robust business in a rapidly growing market. We have expectations to participate in the fast growing pan-Asian health care industry and specifically the increasing demand for wound care in China."
TWSI currently traded on the OTCQB exchange, and has only around 24 million shares issued and outstanding. Based on their growing US and military sales, low shares outstanding, and now entry into the Chinese medical product market, TWSI stock has real potential to make a run back to $1.00 a share again.
TWSI current stock quote
http://www.otcmarkets.com/stock/twsi/quote
About HemCon Medical Technologies, Inc.
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com
Full article and website:
www.wallstreetnewscast.com/news/2015/04/twsi-china-1842.html
$SCRC Stock Could be Positioned for Snap-Back Rally Next Week
By: staff reporter, Melissa Diaz
Last Updated: April 10, 2015 8:05 AM EST
(NEW YORK)--ScripsAmerica, Inc. (OTCBB:SCRC), a leading provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies, may be setting up for a strong rally after a volatile week of price and volume.
SCRC stock experienced a sharp and steep drop earlier this week on stronger than normal volume. Following this event, a number of rumors swirled that there may be some sort of operational issue with their pharmaceutical business, or that a large note holder may had hit the exit button.
Following the sharp decline the Company issued a statement Thursday stating, 'ScripsAmerica (SCRC) knows of no reason relating to its operations that would account for the recent unusual volume and price activity in its stock. The Company has not provided any updates to the extensive discussion of the Company's business as presented in the Company's investor presentation as available on the Company's website, as well as other public disclosure that can be found on the website or filed with the SEC. Furthermore, the Company fully intends to reiterate all of the comments and disclosures at the upcoming 2nd Annual Growth Capital Expo in Las Vegas on Monday, April 13, 2015.'
This news helped alleviate fear that the sharp decline had been due to some operational issues, hence it is probably more likely related to some issue with a current note holder. If true, which remains to be seen, this could set SCRC up for possible sharp spike of recovery as the coming week could provide several catalysts that could increase wild swings within the stock.
Coming Events Next Week
As mentioned in their statement above, SCRC plans to present at the 2nd Annual Growth Capital Expo in Las Vegas this Monday, April 13, 2015. If the Company can show through public disclosure that no material changes were the cause for this weeks sharp drop, that could provide a real boast of confidence, which could spell for a very active start for the company trading week.
The next big event to occur next week that could spur a snap-back in the stock is their fiscal 2014 financial earnings. If the Company can show strong earnings growth, which is expected, and better yet provide that guidance remains strong for fiscal 2015, this weeks drop in share price could spell a spring time Christmas gift for traders.
Third Quarter 2014 Financial Results
The Company reported $12,817,000 in Net Revenue during the three months ended September 30, 2014 compared to $73,000 reported during the same period in 2013, marking an increase of $12,744,000 in quarterly revenue YoY. The Company's Net Revenue from operations during the nine months ended September 30, 2014 was reported as $17,342,000 compared to $452,000 over the same nine month period in 2013, marking an increase of $16,890,000 or 3,737%.
Gross profit for the three months ended September 30, 2014 was $11,604,000 compared to $43,000 for the same period in 2013, which is an increase of $11,561,000 or 26,886%. For the nine month period ended September 30, 2014, gross profit for the Company was approximately $15,525,343, which was 90% of its net sales as compared to a gross profit of approximately $27,783 for the same period in 2013 for an increase of approximately $15,497,560.
The Company's increase in gross profit from 2014 to 2013 can be attributed to its management of Main Avenue Pharmacy, which generated significant sales in the first nine months of 2014 and has a gross margin percentage ranging from 85% to 91%.
SCRC closed up 17% Thursday to a price of $0.078 per share, on volume of around 2.9 million shares traded.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com
$SCRC Stock Could be Positioned for Snap-Back Rally Next Week
By: staff reporter, Melissa Diaz
Last Updated: April 10, 2015 8:05 AM EST
(NEW YORK)--ScripsAmerica, Inc. (OTCBB:SCRC), a leading provider of a range of specialty prescription and over the counter pharmaceuticals and medical supplies, may be setting up for a strong rally after a volatile week of price and volume.
SCRC stock experienced a sharp and steep drop earlier this week on stronger than normal volume. Following this event, a number of rumors swirled that there may be some sort of operational issue with their pharmaceutical business, or that a large note holder may had hit the exit button.
Following the sharp decline the Company issued a statement Thursday stating, 'ScripsAmerica (SCRC) knows of no reason relating to its operations that would account for the recent unusual volume and price activity in its stock. The Company has not provided any updates to the extensive discussion of the Company's business as presented in the Company's investor presentation as available on the Company's website, as well as other public disclosure that can be found on the website or filed with the SEC. Furthermore, the Company fully intends to reiterate all of the comments and disclosures at the upcoming 2nd Annual Growth Capital Expo in Las Vegas on Monday, April 13, 2015.'
This news helped alleviate fear that the sharp decline had been due to some operational issues, hence it is probably more likely related to some issue with a current note holder. If true, which remains to be seen, this could set SCRC up for possible sharp spike of recovery as the coming week could provide several catalysts that could increase wild swings within the stock.
Coming Events Next Week
As mentioned in their statement above, SCRC plans to present at the 2nd Annual Growth Capital Expo in Las Vegas this Monday, April 13, 2015. If the Company can show through public disclosure that no material changes were the cause for this weeks sharp drop, that could provide a real boast of confidence, which could spell for a very active start for the company trading week.
The next big event to occur next week that could spur a snap-back in the stock is their fiscal 2014 financial earnings. If the Company can show strong earnings growth, which is expected, and better yet provide that guidance remains strong for fiscal 2015, this weeks drop in share price could spell a spring time Christmas gift for traders.
Third Quarter 2014 Financial Results
The Company reported $12,817,000 in Net Revenue during the three months ended September 30, 2014 compared to $73,000 reported during the same period in 2013, marking an increase of $12,744,000 in quarterly revenue YoY. The Company's Net Revenue from operations during the nine months ended September 30, 2014 was reported as $17,342,000 compared to $452,000 over the same nine month period in 2013, marking an increase of $16,890,000 or 3,737%.
Gross profit for the three months ended September 30, 2014 was $11,604,000 compared to $43,000 for the same period in 2013, which is an increase of $11,561,000 or 26,886%. For the nine month period ended September 30, 2014, gross profit for the Company was approximately $15,525,343, which was 90% of its net sales as compared to a gross profit of approximately $27,783 for the same period in 2013 for an increase of approximately $15,497,560.
The Company's increase in gross profit from 2014 to 2013 can be attributed to its management of Main Avenue Pharmacy, which generated significant sales in the first nine months of 2014 and has a gross margin percentage ranging from 85% to 91%.
SCRC closed up 17% Thursday to a price of $0.078 per share, on volume of around 2.9 million shares traded.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com
$TWSI medical supply contract in China (ask .25)
TWSI begins selling their medical products in China
http://www.otcmarkets.com/stock/TWSI/news
just reported revenues up in 2014 to $5.5 million, expected to become profitable in 2015.
Ask .25 now, which is breakout on the chart as you can see below...dont miss the run!
$TWSI medical supply contract in China (ask .25)
TWSI begins selling their medical products in China
http://www.otcmarkets.com/stock/TWSI/news
just reported revenues up in 2014 to $5.5 million, expected to become profitable in 2015.
Ask .25 now, which is breakout on the chart as you can see below...dont miss the run!
$TWSI medical supply contract in China (ask .25)
TWSI begins selling their medical products in China
http://www.otcmarkets.com/stock/TWSI/news
just reported revenues up in 2014 to $5.5 million, expected to become profitable in 2015.
Ask .25 now, which is breakout on the chart as you can see below...dont miss the run!
$TWSI medical supply contract in China (ask .25)
TWSI begins selling their medical products in China
http://www.otcmarkets.com/stock/TWSI/news
just reported revenues up in 2014 to $5.5 million, expected to become profitable in 2015.
Ask .25 now, which is breakout on the chart as you can see below...dont miss the run!